243 related articles for article (PubMed ID: 12794765)
1. Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells.
Miao ZH; Tang T; Zhang YX; Zhang JS; Ding J
Int J Cancer; 2003 Aug; 106(1):108-15. PubMed ID: 12794765
[TBL] [Abstract][Full Text] [Related]
2. Transcription factor c-Jun activation represses mdr-1 gene expression.
Miao ZH; Ding J
Cancer Res; 2003 Aug; 63(15):4527-32. PubMed ID: 12907627
[TBL] [Abstract][Full Text] [Related]
3. Reactive oxygen species contribute to cell killing and P-glycoprotein downregulation by salvicine in multidrug resistant K562/A02 cells.
Cai Y; Lu J; Miao Z; Lin L; Ding J
Cancer Biol Ther; 2007 Nov; 6(11):1794-9. PubMed ID: 18032928
[TBL] [Abstract][Full Text] [Related]
4. Characterization of salvicine-resistant lung adenocarcinoma A549/SAL cell line.
Miao ZH; Tong LJ; Zhang JS; Han JX; Ding J
Int J Cancer; 2004 Jul; 110(5):627-32. PubMed ID: 15146550
[TBL] [Abstract][Full Text] [Related]
5. Induction of actin disruption and downregulation of P-glycoprotein expression by solamargine in multidrug-resistant K562/A02 cells.
Li X; Zhao Y; Ji M; Liu SS; Cui M; Lou HX
Chin Med J (Engl); 2011 Jul; 124(13):2038-44. PubMed ID: 22088467
[TBL] [Abstract][Full Text] [Related]
6. DNA damage, c-myc suppression and apoptosis induced by the novel topoisomerase II inhibitor, salvicine, in human breast cancer MCF-7 cells.
Lu HR; Meng LH; Huang M; Zhu H; Miao ZH; Ding J
Cancer Chemother Pharmacol; 2005 Mar; 55(3):286-94. PubMed ID: 15592835
[TBL] [Abstract][Full Text] [Related]
7. Actinomycin D inhibiting K562 cell apoptosis elicited by salvicine but not decreasing its cytotoxicity.
Qing C; Miao ZH; Tong LJ; Zhang JS; Ding J
Acta Pharmacol Sin; 2003 May; 24(5):415-21. PubMed ID: 12740176
[TBL] [Abstract][Full Text] [Related]
8. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX
Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236
[TBL] [Abstract][Full Text] [Related]
9. Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation.
Meng LH; Ding J
Acta Pharmacol Sin; 2007 Sep; 28(9):1460-5. PubMed ID: 17723179
[TBL] [Abstract][Full Text] [Related]
10. Reversal effect of a macrocyclic bisbibenzyl plagiochin E on multidrug resistance in adriamycin-resistant K562/A02 cells.
Shi YQ; Qu XJ; Liao YX; Xie CF; Cheng YN; Li S; Lou HX
Eur J Pharmacol; 2008 Apr; 584(1):66-71. PubMed ID: 18304528
[TBL] [Abstract][Full Text] [Related]
11. Reactive oxygen species elicit apoptosis by concurrently disrupting topoisomerase II and DNA-dependent protein kinase.
Lu HR; Zhu H; Huang M; Chen Y; Cai YJ; Miao ZH; Zhang JS; Ding J
Mol Pharmacol; 2005 Oct; 68(4):983-94. PubMed ID: 16024664
[TBL] [Abstract][Full Text] [Related]
12. [Asiaticoside inducing apoptosis of tumor cells and enhancing anti-tumor activity of vincristine].
Huang YH; Zhang SH; Zhen RX; Xu XD; Zhen YS
Ai Zheng; 2004 Dec; 23(12):1599-604. PubMed ID: 15601545
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation.
Shi R; Peng H; Yuan X; Zhang X; Zhang Y; Fan D; Liu X; Xiong D
J Cell Biochem; 2013 Aug; 114(8):1890-900. PubMed ID: 23494858
[TBL] [Abstract][Full Text] [Related]
14. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds.
Kars MD; Iseri OD; Gündüz U; Ural AU; Arpaci F; Molnár J
Anticancer Res; 2006; 26(6B):4559-68. PubMed ID: 17201178
[TBL] [Abstract][Full Text] [Related]
15. L1EPO, a novel podophyllotoxin derivative overcomes P-glycoprotein-mediated multidrug resistance in K562/A02 cell line.
Chen H; Wang J; Zhang J; Wang Y; Cao B; Bai S; Yu PF; Bi W; Xie W
Biol Pharm Bull; 2009 Apr; 32(4):609-13. PubMed ID: 19336892
[TBL] [Abstract][Full Text] [Related]
16. [Role of high mobility group box 1 in adriamycin-induced apoptosis in leukemia K562 cells].
Yu Y; Xie M; He YL; Xu WQ; Zhu S; Cao LZ
Ai Zheng; 2008 Sep; 27(9):929-33. PubMed ID: 18799030
[TBL] [Abstract][Full Text] [Related]
17. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.
Misra R; Sahoo SK
Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667
[TBL] [Abstract][Full Text] [Related]
18. Ligustrazine derivate DLJ14 reduces multidrug resistance of K562/A02 cells by modulating GSTπ activity.
Song YN; Guo XL; Zheng BB; Liu XY; Dong X; Yu LG; Cheng YN
Toxicol In Vitro; 2011 Jun; 25(4):937-43. PubMed ID: 21402141
[TBL] [Abstract][Full Text] [Related]
19. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide reduces drug resistance to adriamycin in leukemic K562/A02 cells via multiple mechanisms.
Zhao D; Jiang Y; Dong X; Liu Z; Qu B; Zhang Y; Ma N; Han Q
Biomed Pharmacother; 2011 Aug; 65(5):354-8. PubMed ID: 21775093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
